CSF3 and acute myeloid leukemia: In this randomized clinical trial of fludarabine, cytarabine, and Idarubicin ± ATRA ± G-CSF, the addition of ATRA to intensive chemotherapy did not improve the outcome (CR, OS, EFS, and RFS) of patients with non-APL AML (8).